Pancreatic Neuroendocrine Tumor - 45 Studies Found
Completed |
: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. : Pancreatic Neuroendocrine Tumors (pNET) : 2012-07-06 : Drug: BEZ235 (Stage 1) The investigational study drug used in this trial was BEZ235, which was supplied |
Active, not recruiting |
: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors : Pancreatic Neuroendocrine Tumor : 2007-12-17 :
|
Recruiting |
: Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria : Pancreatic Neuroendocrine Tumors : 2016-07-20 |
Completed |
: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors : Pancreatic Neuroendocrine Tumors : 2010-05-10 : Drug: Sunitinib Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg |
Recruiting |
: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors : Pancreatic Neuroendocrine Tumors : 2014-10-15 : Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
Not yet recruiting |
: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib : Pancreatic Neuroendocrine Tumour Metastatic : 2016-03-16 : Drug: Sunitinib Sunitinib 37.5 mg/day |
Completed |
: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor : Advanced Well-differentiated Pancreatic Neuroendocrine Tumor : 2013-04-29 : Drug: temozolomide or dacarbazine-based chemotherapy, endostatin |
Recruiting |
: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors : Gastro-entero-pancreatic Neuroendocrine Tumors : 2016-04-07 :
|
Not yet recruiting |
: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment : Pancreatic Neuroendocrine Tumors in MEN1 : 2016-03-02 : Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied. |
Terminated |
: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors : Pancreatic Neuroendocrine Tumors (pNET) : 2012-06-25 :
|